The p160 ER co-regulators predict outcome in ER negative breast cancer

Breast Cancer Research and Treatment

Volumn 131, Issue 2, 2012, Pages 463-472

  Spears, Melanie ^a   Oesterreich, Steffi ^b   Migliaccio, Ilenia ^b,c   Guiterrez, Carolina ^b   Hilsenbeck, Susan ^b   Quintayo, Mary Anne ^a   Pedraza, Johanna ^a   Munro, Alison F ^a   Thomas, Jeremy St J ^a   Kerr, Gill R ^a   Jack, Wilma J L ^a   Kunkler, Ian H ^a   Cameron, David A ^a   Chetty, Udi ^a   Bartlett, John M S ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

AIB1; Breast cancer; SRC1; SRC2

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; NUCLEAR RECEPTOR COACTIVATOR 2; PROGESTERONE RECEPTOR; PROTEIN P160; STEROID RECEPTOR COACTIVATOR 1; STEROID RECEPTOR COACTIVATOR 3; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RELAPSE; COHORT ANALYSIS; CONTROLLED STUDY; DISTANT RECURRENCE FREE SURVIVAL; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FAMILY; RECURRENCE FREE SURVIVAL;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NUCLEAR RECEPTOR COACTIVATOR 3; NUCLEAR RECEPTOR COACTIVATORS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS;

EID: 84856217370     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1426-1     Document Type: Article

References (25)

1. D Al-azawi MM Ilroy G Kelly AM Redmond FT Bane S Cocchiglia AD Hill LS Young 2008 Ets-2 and p160 proteins collaborate to regulate c-Myc in endocrine resistant breast cancer Oncogene 27 3021 3031 18059336 10.1038/sj.onc.1210964 1:CAS:528:DC%2BD1cXlsFClt74%3D (Pubitemid 351668011)
2. J Edwards NS Krishna KM Grigor JM Bartlett 2003 Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer Br J Cancer 89 552 556 12888829 10.1038/sj.bjc.6601127 1:CAS:528:DC%2BD3sXlsl2rsb4%3D (Pubitemid 37026442)
3. FJ Fleming AD Hill EW McDermott NJ O'Higgins LS Young 2004 Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer J Clin Endocrinol Metab 89 375 383 14715875 10.1210/jc.2003-031048 1:CAS:528:DC%2BD2cXmvFChtg%3D%3D (Pubitemid 38183907)
4. FJ Fleming E Myers G Kelly TB Crotty EW McDermott NJ O'Higgins AD Hill LS Young 2004 Expression of SRC-1, AIB1, and PEA3 in HER2 mediated endocrine resistant breast cancer; a predictive role for SRC-1 J Clin Pathol 57 1069 1074 15452162 10.1136/jcp.2004.016733 1:CAS:528:DC%2BD2cXps1Kls7Y%3D (Pubitemid 39331358)
5. AR Green C Burney CJ Granger EC Paish S El-Sheikh EA Rakha DG Powe RD Macmillan IO Ellis E Stylianou 2008 The prognostic significance of steroid receptor co-regulators in breast cancer: co-repressor NCOR2/SMRT is an independent indicator of poor outcome Breast Cancer Res Treat 110 427 437 17902051 10.1007/s10549-007-9737-y 1:CAS:528:DC%2BD1cXosVOgt70%3D (Pubitemid 351962584)
6. M Harigopal J Heymann S Ghosh V Anagnostou RL Camp DL Rimm 2009 Estrogen receptor co-activator (AIB1) protein expression by automated quantitative analysis (AQUA) in a breast cancer tissue microarray and association with patient outcome Breast Cancer Res Treat 115 77 85 18521745 10.1007/s10549-008- 0063-9 1:CAS:528:DC%2BD1MXkvVyru7c%3D
7. T Kirkegaard CJ Witton LM McGlynn SM Tovey B Dunne A Lyon JM Bartlett 2005 AKT activation predicts outcome in breast cancer patients treated with tamoxifen J Pathol 207 139 146 16088978 10.1002/path.1829 1:CAS:528: DC%2BD2MXhtFKnsr7P (Pubitemid 41404144)
8. T Kirkegaard J Edwards S Tovey LM McGlynn SN Krishna R Mukherjee L Tam AF Munro B Dunne JM Bartlett 2006 Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology 48 787 794 16722926 10.1111/j.1365-2559.2006.02412.x 1:STN:280:DC%2BD283ptleqsw%3D%3D (Pubitemid 43800937)
9. T Kirkegaard LM McGlynn FM Campbell S Muller SM Tovey B Dunne KV Nielsen TG Cooke JM Bartlett 2007 Amplified in breast cancer 1 in human epidermal growth factor receptor-positive tumors of tamoxifen-treated breast cancer patients Clin Cancer Res 13 1405 1411 17332282 10.1158/1078-0432.CCR-06-1933 1:CAS:528:DC%2BD2sXitlSjtro%3D (Pubitemid 46450429)
10. T Lahusen RT Henke BL Kagan A Wellstein AT Riegel 2009 The role and regulation of the nuclear receptor co-activator AIB1 in breast cancer Breast Cancer Res Treat 116 225 237 19418218 10.1007/s10549-009-0405-2 1:CAS:528:DC%2BD1MXntF2nt74%3D
11. SK Lee HJ Kim SY Na TS Kim HS Choi SY Im JW Lee 1998 Steroid receptor coactivator-1 coactivates activating protein-1-mediated transactivations through interaction with the c-Jun and c-Fos subunits J Biol Chem 273 16651 16654 9642216 10.1074/jbc.273.27.16651 1:CAS:528:DyaK1cXkt12itrY%3D (Pubitemid 28311685)
12. BR Leyland-Jones CB Ambrosone J Bartlett MJ Ellis RA Enos A Raji MR Pins JA Zujewski SM Hewitt JF Forbes M Abramovitz S Braga F Cardoso N Harbeck C Denkert SD Jewell 2008 Recommendations for collection and handling of specimens from group breast cancer clinical trials J Clin Oncol 26 5638 5644 18955459 10.1200/JCO.2007.15.1712
13. MC Louie JX Zou A Rabinovich HW Chen 2004 ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance Mol Cell Biol 24 5157 5171 15169882 10.1128/MCB.24.12.5157-5171.2004 1:CAS:528:DC%2BD2cXkvFOqtro%3D (Pubitemid 38738153)
14. S Massarweh CK Osborne CJ Creighton L Qin A Tsimelzon S Huang H Weiss M Rimawi R Schiff 2008 Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function Cancer Res 68 826 833 18245484 10.1158/0008-5472.CAN-07-2707 1:CAS:528:DC%2BD1cXhtlygtrY%3D (Pubitemid 351206760)
15. LM McShane DG Altman W Sauerbrei SE Taube M Gion GM Clark 2006 REporting recommendations for tumor MARKer prognostic studies (REMARK) Breast Cancer Res Treat 100 229 235 16932852 10.1007/s10549-006-9242-8 (Pubitemid 44631925)
16. E Myers AD Hill G Kelly EW McDermott NJ O'Higgins Y Buggy LS Young 2005 Associations and interactions between Ets-1 and Ets-2 and coregulatory proteins, SRC-1, AIB1, and NCoR in breast cancer Clin Cancer Res 11 2111 2122 15788656 10.1158/1078-0432.CCR-04-1192 1:CAS:528:DC%2BD2MXisFajtb0%3D (Pubitemid 40490167)
17. SY Na SK Lee SJ Han HS Choi SY Im JW Lee 1998 Steroid receptor coactivator-1 interacts with the p50 subunit and coactivates nuclear factor kappaB-mediated transactivations J Biol Chem 273 10831 10834 9556555 10.1074/jbc.273.18.10831 1:CAS:528:DyaK1cXjtFGktrw%3D (Pubitemid 28204916)
18. CK Osborne 1998 Tamoxifen in the treatment of breast cancer N Engl J Med 339 1609 1618 9828250 10.1056/NEJM199811263392207 1:CAS:528:DyaK1cXnvFOitLs%3D (Pubitemid 28536137)
19. CK Osborne V Bardou TA Hopp GC Chamness SG Hilsenbeck SA Fuqua J Wong DC Allred GM Clark R Schiff 2003 Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer J Natl Cancer Inst 95 353 361 12618500 10.1093/jnci/95.5.353 1:CAS:528:DC%2BD3sXivVeqsrg%3D (Pubitemid 36395255)
20. CK Osborne J Shou S Massarweh R Schiff 2005 Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer Clin Cancer Res 11 865s 870s 15701879 1:CAS:528:DC%2BD2MXislWgu7k%3D (Pubitemid 40111098)
21. L Qin L Liao A Redmond L Young Y Yuan H Chen BW O'Malley J Xu 2008 The AIB1 oncogene promotes breast cancer metastasis by activation of PEA3-mediated matrix metalloproteinase 2 (MMP2) and MMP9 expression Mol Cell Biol 28 5937 5950 18644862 10.1128/MCB.00579-08 1:CAS:528:DC%2BD1cXhtF2gt7rO
22. AM Redmond FT Bane AT Stafford M McIlroy MF Dillon TB Crotty AD Hill LS Young 2009 Coassociation of estrogen receptor and p160 proteins predicts resistance to endocrine treatment; SRC-1 is an independent predictor of breast cancer recurrence Clin Cancer Res 15 2098 2106 19276281 10.1158/1078-0432.CCR- 08-1649 1:CAS:528:DC%2BD1MXjtF2rtbo%3D
23. MI Torres-Arzayus J Zhao R Bronson M Brown 2010 Estrogen-dependent and estrogen-independent mechanisms contribute to AIB1-mediated tumor formation Cancer Res 70 4102 4111 20442283 10.1158/0008-5472.CAN-09-4080 1:CAS:528:DC%2BC3cXlvFyqs7s%3D
24. S Tovey B Dunne CJ Witton A Forsyth TG Cooke JM Bartlett 2005 Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? Clin Cancer Res 11 4835 4842 16000581 10.1158/1078-0432.CCR-05-0196 1:CAS:528:DC%2BD2MXlvVGgs74%3D (Pubitemid 41557203)
25. S Wang Y Yuan L Liao SQ Kuang JC Tien BW O'Malley J Xu 2009 Disruption of the SRC-1 gene in mice suppresses breast cancer metastasis without affecting primary tumor formation Proc Natl Acad Sci USA 106 151 156 19109434 10.1073/pnas.0808703105 1:CAS:528:DC%2BD1MXlsF2qsg%3D%3D